ArticleJournal of neuro-oncology2016
A cure is possible: a study of 10-year survivors of brain metastases.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Survival, quality of life, and motor function in brain metastases surgery: The role of complete resection.Neuro-oncology practice · 2025Article
- Astrocytes are enablers of brain metastases.Nature cell biology · 2024Article
- Five-year survivors from brain metastases treated with stereotactic radiosurgery: Biology, improving treatments, or just plain luck?Neuro-oncology practice · 2023Article
- Editorial: Effects of radiation therapies on brain metastases.Frontiers in oncology · 2023Article
- Biliary cancer brain metastases: a multi-institution case series with case reports.Journal of gastrointestinal oncology · 2022Article
- Non-small cell lung cancer with multiple brain metastases remains relapse-free for more than 13 years: A case report.Molecular and clinical oncology · 2022Article
- Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients.Current oncology (Toronto, Ont.) · 2021Article
- Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.Neuro-oncology · 2020Article
- Brain Metastases as a First Site of Recurrence in Patients Receiving Chemotherapy with Controlled Systemic Cancer: a Critical but Under-Recognized Clinical Scenario.Current treatment options in neurology · 2019Review
- Cognitive Decline Secondary to Therapeutic Brain Radiation-Similarities and Differences to Traumatic Brain Injury.Brain sciences · 2019Article
- Factors associated with long-term survival in central nervous system metastases.Journal of neuro-oncology · 2018Article
- The risk of cataractogenesis after gamma knife radiosurgery: a nationwide population based case-control study.BMC ophthalmology · 2017Article
- Gamma Knife treatment of recurrent CNS metastases of pancreatic origin: a case report and review of the literature.CNS oncology · 2017Review
- Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.Neuro-oncology advancesArticle
- Long-term survival results after treatment for oligometastatic brain disease.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known on the natural history, recurrence patterns, neurocognitive outcomes and prognostic factors associated with survival in long-term survivors (≥10 years) from brain metastasis (BM). In this study, the records of 1953 patients who underwent treatment for BM with a potential for ≥10 years of follow-up were reviewed. Cox regression analysis identified factors predictive for overall survival (OS). The median age at brain metastasis diagnosis was 60 years and the median OS was 6.4 months. The 1-year OS rate was 29.9, 12.1 % at 2 years, 3.0 % at 5 years, and 1.3 % at 10 years. On multivariable analysis, factors associated with worse OS included gender (males, HR 1.2), multiple brain metastases (HR 1.3), no surgery (HR 1.8), and no stereotactic radiosurgery (HR 1.8) (p < 0.0001 each). Fifty-six patients (2.9 %) survived ≥5 years; 23 patients (1.2 %) survived ≥10 years and the median survival for ≥10 year survivors was 18.5 years. Six of the 10-year survivors had an intracranial recurrence, five occurred within 11 years from the first treatment. Presence of a solitary lesion or single lesion at the time of brain metastasis diagnosis was associated with improved survival. Eight of the ≥10 year survivors (34.8 %) had no neurological symptoms at last follow-up; none of the 10-year survivors were documented to have a neurologic death. Our study demonstrates that patients with favorable prognostic features should undergo multimodality treatment. Albeit rare, patients who are alive 10 years after treatment for their brain metastases may be considered cured from their intracranial disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.